Social Media Ideas for Gsk

<![CDATA[GSK Enters $10.6 Billion Agreement to Acquire Nuvalent Inc. ]]>

GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm

Nuvalent’s late-stage lung cancer treatments zidesamtinib and neladalkib are expected to launch later this yearBusiness live – latest updatesGSK’s new boss, Luke Miels, has struck...

<![CDATA[Pharmaceutical Executive Daily: GSK Acquires Nuvalent for $10.6 Billion]]>

GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment Transcript

GSK: Improved Prospects After Correction

GSK pledges £44.5M in near term for UK biotech to explore cause of liver fibrosis regression

GSK’s latest hepatology partnership is posing a less-asked question—how do you encourage the regression of patients’ liver fibrosis?

GSK sees phase 3 win for Hansoh-partnered ADC in China as validating its ‘priority asset’

Hansoh Pharmaceutical’s pair of much-hyped ADCs continue to justify partner GSK’s decision to make them priority programs.

GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancer

GSK has struck a deal to buy Nuvalent for $10.6 billion, securing two near-approval cancer therapies that could challenge products from Roche, Pfizer and other drugmakers.

GSK boosts cancer pipeline with $11B Nuvalent buyout

The British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.

GSK to Acquire Nuvalent for $10.6B, Boosting Cancer Pipeline with Precision NSCLC Treatments

Nuvalent’s pipeline is headed by the ROS1 inhibitor zidesamtinib (NVL-520) and the ALK inhibitor eladalkib (NVL-655), which according to the company represent potential best-in-cla...

GSK, Hansoh ADC extends survival in lung cancer study

GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers. 

GSK steps up cancer fight as new boss Luke Miels signals a change of direction: ALEX BRUMMER

The choice of Aussie Luke Miels as GSK's chief exec, previously a lieutenant of Pascal Soriot at AstraZeneca, signalled a change of direction.

GSK strikes deal to buy lung cancer drugmaker Nuvalent for $10.6bn

Nuvalent's key asset is a drug called neladalkib, a therapy which targets certain types of lung cancer.

GSK Eyes FDA Filing After Immunotherapy Succeeds in Key Rectal Cancer Study

GSK drug Jemperli met the main goal of a pivotal Phase 2 test in patients with a rare type of rectal cancer, paving the way for regulatory submissions. This antibody drug has alrea...

GSK ends brain drug alliance with Alector

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.

GSK Gets a Pair of Near-Commercial Lung Cancer Drugs via $10.6B Nuvalent Acquisition

GSK’s Nuvalent acquisition brings two lead programs, each addressing different targets for non-small cell lung cancer. The Nuvalent lung cancer drugs are under FDA review and if th...

GSK cuts losses on $700M upfront Alzheimer’s collab with Alector following 2 clinical failures

GSK has walked away from a $2.2 billion biobucks neurodegenerative disease pact with Alector that has seen both “next generation” drugs involved flunk clinical trials.

See what £13,000 invested in GSK shares 3 months ago is worth today…

Harvey Jones was thrilled with the performance of his GSK shares, but lately it's all gone a bit flat. Could the recent dip be a buying opportunity? The post See what £13,000 inves...

GSK in talks to buy cancer drugmaker Nuvalent for over $9 bln, FT reports

AstraZeneca, GSK intensify China ties with Sino Biopharm deals

The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions in the U.S.

Key deals this week: GSK, Incyte, Ingredion, OpenAI, and more

GSK’s hepatitis B drug cures one-fifth of patients in ‘major step’ for pervasive disease

GSK is pulling back the curtain on the phase 3 success of its chronic hepatitis B drug bepirovirsen, revealing that nearly one-fifth of all treated patients across two trials were...

GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’

The findings supporting bepirovirsen were deemed a “historic moment” by physicians and validate a drug that has “clear blockbuster potential,” according to one analyst.

GVRP, StepsBio set up CoE for formulations R&D in Bengaluru

GSRC is designed to tackle complex formulation challenges by combining advanced scientific infrastructure with specialised workflows for drug delivery systems, sterile injectables,...